Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells $410,000.00 in Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Arturo Md Molina sold 5,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $82.00, for a total value of $410,000.00. Following the sale, the insider directly owned 84,115 shares of the company’s stock, valued at approximately $6,897,430. This trade represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Arturo Md Molina also recently made the following trade(s):

• On Friday, January 23rd, Arturo Md Molina sold 13,151 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $82.42, for a total transaction of $1,083,905.42.
• On Tuesday, January 20th, Arturo Md Molina sold 9,514 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $82.48, for a total transaction of $784,714.72.

Protagonist Therapeutics Trading Down 2.5%

PTGX opened at $79.73 on Friday. Protagonist Therapeutics, Inc. has a 12 month low of $33.70 and a 12 month high of $96.54. The stock has a fifty day moving average price of $86.33 and a 200-day moving average price of $72.53. The firm has a market cap of $4.98 billion, a price-to-earnings ratio of 128.60 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The firm had revenue of $4.71 million during the quarter, compared to the consensus estimate of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. On average, equities research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Institutional Trading of Protagonist Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its holdings in Protagonist Therapeutics by 30.6% in the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock worth $482,000 after acquiring an additional 2,334 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Protagonist Therapeutics by 0.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock worth $1,810,000 after purchasing an additional 348 shares in the last quarter. Millennium Management LLC raised its position in shares of Protagonist Therapeutics by 283.6% during the 1st quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock worth $6,493,000 after purchasing an additional 99,269 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in Protagonist Therapeutics by 11.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 36,906 shares of the company’s stock valued at $2,039,000 after buying an additional 3,883 shares in the last quarter. Finally, Precision Wealth Strategies LLC acquired a new stake in Protagonist Therapeutics in the 2nd quarter worth about $793,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on PTGX. Truist Financial lifted their price target on Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Weiss Ratings upgraded Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, December 24th. BMO Capital Markets reiterated an “outperform” rating on shares of Protagonist Therapeutics in a report on Monday, October 13th. Citizens Jmp lifted their price objective on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Protagonist Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $86.77.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.